BIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Rad Laboratories Inc (BIO) is not a strong buy for a beginner, long-term investor at this time. The stock shows weak financial performance, negative analyst sentiment, and lacks positive catalysts. While hedge funds are buying, the company's growth engine faces challenges, and there is no strong technical or proprietary trading signal to justify immediate entry.
The MACD is positive but contracting, RSI is neutral at 53.815, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot point of 276.48, with resistance at 285.835 and support at 267.124. Overall, the technical indicators suggest a lack of strong momentum in either direction.
Hedge funds are significantly increasing their positions in the stock, with a 333305.80% increase in buying over the last quarter.
Analysts have downgraded the stock due to challenges in the process chromatography business and uncertainties in the China diagnostics market. Financial performance in Q4 2025 showed declining net income (-200.59% YoY) and EPS (-204.22% YoY). No recent news or congress trading data to indicate positive sentiment.
In Q4 2025, revenue increased by 3.85% YoY to $693.2M, but net income dropped significantly by -200.59% YoY to $720M. EPS also fell by -204.22% YoY to 26.65, and gross margin declined by -2.89% YoY to 49.74%. These metrics indicate weak financial performance and profitability.
Recent analyst ratings are negative. Citi downgraded the stock to Neutral from Buy with a reduced price target of $300 (down from $375), citing challenges in the company's growth engine. Wells Fargo and UBS also lowered price targets, highlighting weak guidance and margin concerns.
